| Line Item | 2026-04-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $38K | -59.6% | -20.2% |
| Gross Profit | $38K | — | -20.2% |
| SG&A Expense | $612K | -14.2% | -54.0% |
| Pre-tax Income | -$575K | +7.4% | +71.2% |
| Income Tax | -$19K | — | — |
| Net Income | -$575K | +7.4% | +71.2% |
| EPS (Basic) | -$0.04 |
| Line Item | 2026-04-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $0 | — | — |
| Accounts Receivable | $80K | -33.3% | +14.3% |
| Current Assets | $424K | -54.5% | -78.2% |
| Total Assets | $424K | -54.5% | -96.5% |
| Current Liabilities | $444K | +2.3% | -57.0% |
| Total Liabilities | $444K |
| Line Item | 2026-04-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.2M | -55.8% | — |
| Investing Cash Flow | -$100K | — | — |
| Financing Cash Flow | $1.0M | +0.0% | — |
Business Overview
Kaival Brands Innovations Group is a holding company that historically distributed ENDS products (BIDI Stick) in the U.S. but has transitioned to focus on royalty revenue from an international licensing agreement with Philip Morris Products S.A. and development of intellectual property assets. Beginning in 2024, the Company significantly reduced and ultimately ceased its ENDS distribution activities due to FDA marketing denial orders and patent litigation, with primary revenue now derived from PMI royalties under the June 2022 international licensing agreement.
Segment Performance
The Company operates primarily through royalty revenue from the PMI License Agreement rather than traditional business segments. For the six months ended April 30, 2026, total revenues were $130,468 ($37,530 product revenue and $92,938 royalty revenue) compared to $249,648 for the prior year period ($4,073 product revenue and $245,575 royalty revenue), representing a 48% decline. The Company recorded a net loss of $1,195,331 for six months ended April 30, 2026 versus $6,058,733 in the prior year period. Royalty revenue specifically declined from $202,893 to $130,468 (36% decrease) comparing the three-month periods.
Forward Guidance
No specific financial guidance or targets are provided. The filing contains extensive forward-looking statement disclaimers, cautioning that forward-looking statements involve "significant risks, uncertainties and other factors" and that "actual results, performance, or achievements...may be materially different from any future results." The Company states it undertakes "no obligation to publicly update or revise any forward-looking statements" and cautions that "potential investors should not make an investment decision based solely on our projections, estimates or expectations."
Key Risk Factors
The Company faces substantial risks including: (1) the ongoing ITC patent infringement complaint against Bidi and the Company by R.J. Reynolds entities regarding the BIDI Stick, which prevents import and sale of the product; (2) FDA marketing denial orders issued in January 2024 for Classic BIDI Stick and November 2025 for non-tobacco flavored BIDI Sticks, which could have substantial adverse impact; (3) heavy reliance on PMI for royalty revenue, which is currently the primary revenue source, and the company's ability to raise required funding in debt or equity; and (4) uncertain value realization from intellectual property assets acquired from GoFire, Inc.
| +76.5% |
| EPS (Diluted) | -$0.04 | +20.0% | +76.5% |
| +2.3% |
| -72.0% |
| Stockholders' Equity | -$21K | -104.2% | -100.2% |